{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:18Z","timestamp":1792723098410,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.farma.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:16Z","timestamp":1792720456000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Farmacogen\u00e9tica en oncolog\u00eda pedi\u00e1trica: evidencia actual y desaf\u00edos para su implementaci\u00f3n cl\u00ednica"],"prefix":"10.1016","author":[{"given":"Elena","family":"Rodr\u00edguez-Espa\u00f1a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Fern\u00e1ndez-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Belaustegi-Foronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bernardez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/cancers18030362","article-title":"Spanish pediatric hematology and oncology survival results and trends, 1999\u20132022","volume":"18","author":"Alfonso-Comos","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.farma.2026.09.011_bb0010","series-title":"C\u00e1ncer infantil en Espa\u00f1a. Estad\u00edsticas 1980\u20132023. Registro espa\u00f1ol de tumores infantiles (RETI-SEHOP)","author":"Ca\u00f1ete Nieto","year":"2024"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0025","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70246","article-title":"Frequency and implications of high-risk pharmacogenomic phenotypes identified in a diverse Australian pediatric oncology cohort","volume":"18","author":"Moore","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cpt.3685","article-title":"Implementing pre-emptive pharmacogenetics: impact of early pharmacogenetic screening in a pediatric oncology cohort of 1151 subjects","volume":"118","author":"Bernsen","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-023-03598-x","article-title":"Challenges of pediatric pharmacotherapy: a narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"80","author":"Watanabe","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0040","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.farma.2026.09.011_bb0045","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"10.1016\/j.farma.2026.09.011_bb0050","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41431-022-01243-2","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan","volume":"31","author":"Hulshof","year":"2023","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.farma.2026.09.011_bb0060","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cpt.70209","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update","volume":"119","author":"Maillard","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.farma.2026.09.011_bb0095","first-page":"369","article-title":"Influence of UGT1A1 *6\/*28 polymorphisms on irinotecan-related toxicity and survival in pediatric patients with relapsed\/refractory solid tumors treated with the VIT regimen","volume":"14","author":"Zhu","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/fcp.12117","article-title":"UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice","volume":"29","author":"Etienne-Grimaldi","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.farma.2026.09.011_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1568320","article-title":"Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis","volume":"16","author":"Wong","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bcp.13008","article-title":"Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity","volume":"82","author":"Aminkeng","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.farma.2026.09.011_bb0145","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3390\/cancers13112837","article-title":"Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies","volume":"13","author":"Taylor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00280-024-04694-0","article-title":"Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients","volume":"94","author":"Rahmayanti","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12957-023-03287-0","article-title":"Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis","volume":"22","author":"Liu","year":"2024","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70136","article-title":"The role of candidate polymorphisms in drug transporter genes on high-dose methotrexate in the consolidation phase of the AIEOP-BFM ALL 2009 protocol","volume":"18","author":"Braidotti","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.farma.2026.09.011_bb0170","first-page":"800","article-title":"Polymorphisms within methotrexate pathway genes: relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia","volume":"23","author":"Esmaili","year":"2020","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00431-023-05267-8","article-title":"Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia","volume":"183","author":"Zhou","year":"2024","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0180","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2025.2469373","article-title":"Association between ABCB1 C3435T polymorphism and methotrexate-related toxicity in pediatric acute lymphoblastic leukemia: a meta-analysis","volume":"30","author":"Yan","year":"2025","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41431-022-01180-0","article-title":"Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and allopurinol, and MTHFR, folic acid and methotrexate","volume":"32","author":"van der Pol","year":"2024","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.farma.2026.09.011_bb0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FTD.0000000000000298","article-title":"Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers","volume":"38","author":"Lee","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.farma.2026.09.011_bb0195","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/FTD.0000000000001113","article-title":"Systematic critical review of genetic factors associated with cisplatin-induced ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 update","volume":"45","author":"Scott","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0055","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/jnci\/djae004","article-title":"Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations","volume":"116","author":"Maillard","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/medsci13030112","article-title":"NUDT15 pharmacogenetics in acute lymphoblastic leukemia: synthesizing progress for personalized thiopurine therapy","volume":"13","author":"Lubis","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.farma.2026.09.011_bb0070","author":"Ministerio de"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s43440-025-00818-2","article-title":"The role of pharmacogenetics in the therapy regimen of acute lymphoblastic leukemia in children: recent discoveries and future perspectives","volume":"78","author":"Szoszkiewicz","year":"2026","journal-title":"Pharmacol Rep"},{"issue":"14","key":"10.1016\/j.farma.2026.09.011_bb0080","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatin\/vincristine\/fluorouracil and cisplatin\/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group","volume":"18","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12094-021-02708-4","article-title":"Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines","volume":"24","author":"Garc\u00eda-Alfonso","year":"2022","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/pharmaceutics17050542","article-title":"Dose-limiting toxicities and the maximum tolerated dose of irinotecan based on UGT1A1 genotypes: a systematic review","volume":"17","author":"D\u00edaz-Villamar\u00edn","year":"2025","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.farma.2026.09.011_bb0105","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/jcph.2484","article-title":"Development and evaluation of ontogeny functions of the major UDP-glucuronosyltransferase enzymes to underwrite physiologically based pharmacokinetic modeling in pediatric populations","volume":"64","author":"Farhan","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0110","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1124\/dmd.110.037192","article-title":"The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver","volume":"39","author":"Miyagi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.farma.2026.09.011_bb0120","first-page":"884","article-title":"Pediatric cardio-oncology: screening, risk stratification, and prevention of cardiotoxicity associated with anthracyclines","volume":"11","author":"Liu","year":"2024","journal-title":"Children (Basel)"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0125","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","article-title":"Functional validation of doxorubicin-induced cardiotoxicity-related genes","volume":"6","author":"Fonoudi","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"17","key":"10.1016\/j.farma.2026.09.011_bb0140","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1002\/cncr.32948","article-title":"Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer: a children's oncology group ALTE03N1 report","volume":"126","author":"Singh","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28119","article-title":"Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: a single-institution experience","volume":"67","author":"Bernstock","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/FTD.0000000000001085","article-title":"Role of cisplatin dose intensity and TPMT variation in the development of hearing loss in children","volume":"45","author":"Siemens","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"19","key":"10.1016\/j.farma.2026.09.011_bb0205","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO-24-01861","article-title":"Development and validation of a novel prediction model for hearing loss from cisplatin chemotherapy","volume":"43","author":"Millstein","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.farma.2026.09.011_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/OP-25-00913","article-title":"TPMT-cisplatin: lessons in citation integrity and scientific oversight","author":"Cho","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0215","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41397-019-0113-1","article-title":"Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: the International PanCareLIFE Study","volume":"20","author":"Clemens","year":"2020","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.farma.2026.09.011_bb0220","doi-asserted-by":"crossref","first-page":"bcp.70317","DOI":"10.1002\/bcp.70317","article-title":"Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia\u2014a comprehensive review.","author":"de Kluis","year":"2025","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.farma.2026.09.011_bb0225","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40262-022-01173-8","volume":"61","author":"Gatti","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.farma.2026.09.011_bb0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cpt.2969","article-title":"Mechanistic, functional, and clinical aspects of pro-inflammatory cytokine-mediated regulation of ADME gene expression in 3D human liver spheroids","volume":"114","author":"Kl\u00f6ditz","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.farma.2026.09.011_bb0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/17425255.2025.2451440","article-title":"Pharmacogenetic-guided drug therapy: how to deal with phenoconversion in polypharmacy","volume":"21","author":"Stingl","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0240","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/ph14050487","article-title":"The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug\u2013drug interactions: drug-gene, drug-gene\u2013gene and drug\u2013drug-gene interactions","volume":"14","author":"Hahn","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.farma.2026.09.011_bb0245","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70209","article-title":"Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in pediatrics, adolescents and young adults with lymphoma: rationale and design of the PEGASUS study","volume":"18","author":"Conyers","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.c.31391","article-title":"PG4KDS: a model for the clinical implementation of preemptive pharmacogenetics","volume":"166C","author":"Hoffman","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.farma.2026.09.011_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.anpedi.2025.503936","article-title":"Actualizaci\u00f3n de farmacogen\u00e9tica en pediatr\u00eda","volume":"104","author":"Taladriz-Sender","year":"2026","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.farma.2026.09.011_bb0260","series-title":"ALLTogether1: a treatment study protocol of the ALLTogether consortium for children and young adults (0\u201345\u202fyears of age) with newly diagnosed acute lymphoblastic leukemia (ALL)","author":"Heyman","year":"2026"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0265","first-page":"144","article-title":"The critical role of pharmacists in the clinical delivery of pharmacogenetics in the US","volume":"11","author":"Haga","year":"2023","journal-title":"Pharmacy (Basel)"},{"issue":"5","key":"10.1016\/j.farma.2026.09.011_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085115","article-title":"Minimizing adverse drug reactions and verifying economic legitimacy-pharmacogenomics implementation in children (MARVEL-PIC): protocol for a national randomized controlled trial of pharmacogenomics implementation","volume":"14","author":"Conyers","year":"2024","journal-title":"BMJ Open"},{"issue":"suppl 1","key":"10.1016\/j.farma.2026.09.011_bb0275","first-page":"S102","article-title":"Mapping the clinical pharmacokinetics and pharmacogenetic units operating in Spanish hospitals","volume":"45","author":"T\u00e9var-Alfonso","year":"2021","journal-title":"Farm Hosp"},{"issue":"2","key":"10.1016\/j.farma.2026.09.011_bb0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pharmaceutics18020165","article-title":"Pharmacogenomics of antineoplastic therapy in children: genetic determinants of toxicity and efficacy","volume":"18","author":"Dushimova","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.farma.2026.09.011_bb0285","article-title":"Revolutionizing precision oncology: the role of artificial intelligence in personalized pediatric cancer care","volume":"12","author":"Hashem","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063432600228X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113063432600228X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:54:22Z","timestamp":1792720462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113063432600228X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"alternative-id":["S113063432600228X"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.011","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Farmacogen\u00e9tica en oncolog\u00eda pedi\u00e1trica: evidencia actual y desaf\u00edos para su implementaci\u00f3n cl\u00ednica","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}